Kalyan Nagulapalli Venkata*
Although skin prick testing in AR patients is positive (showing the production of antigen-specific Immunoglobulin E), there is no correlation with total circulating IgE levels. There was no correlation between circulating IgE levels and skin prick tests or laboratory testing for specific IgE. Omalizumab binds to uncomplicated IgE more strongly in humans than Fc-epsilon. Omalizumab works by lowering IgE levels and decreasing the development of FceRI receptors (which bind IgE) in mast cells and basophils, resulting in reduced mast cell recruitment and responsiveness and, as a result, less eosinophilic infiltration and activation. Anti-IgE treatment with omalizumab may reduce the lifespan of mast cells and induce dendritic cells to produce less FcRI.
Partagez cet article